|
1.
|
|
8 p, 192.2 KB |
Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates
/
Miller, P.D. (Colorado Center for Bone Research) ;
Pannacciulli, N. (Amgen Inc) ;
Brown, J.P. (Laval University) ;
Czerwinski, E. (Krakow Medical Center) ;
Nedergaard, B.S. (Center for Clinical and Basic Research) ;
Bolognese, M.A. (Bethesda Health Research Center) ;
Malouf Sierra, Jorge 1971- (Institut d'Investigació Biomèdica Sant Pau) ;
Bone, H.G. (Michigan Bone and Mineral Clinic) ;
Reginster, J. Y. (University of Liège) ;
Singer, A. (Georgetown University Medical Center) ;
Wang, C. (Amgen Inc) ;
Wagman, R.B. (Amgen Inc) ;
Cummings, S.R. (California Pacific Medical Center Research Institute) ;
Universitat Autònoma de Barcelona
Denosumab and zoledronic acid (ZOL) are parenteral treatments for patients with osteoporosis. The objective of the study was to compare the effect of transitioning from oral bisphosphonates to denosumab or ZOL on bone mineral density (BMD) and bone turnover. [...]
2016 -  10.1210/jc.2016-1801
The journal of clinical endocrinology & metabolism, Vol. 101 Núm. 8 (august 2016) , p. 3163-3170
|
|
|
2.
|
|
8 p, 594.7 KB |
The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes : Achieving HbA1c targets with basal insulin in a real-world setting
/
Meneghini, Luigi F. (Parkland Health & Hospital System) ;
Mauricio Puente, Dídac (Institut d'Investigació Biomèdica Sant Pau) ;
Orsi, Emanuela (Fondazione Ca' Granda IRCCS) ;
Lalic, Nebojsa M. (University of Belgrade) ;
Cali, Anna M.G. (Sanofi) ;
Westerbacka, Jukka (Sanofi) ;
Stella, Peter (Sanofi) ;
Candelas, Christophe (Sanofi) ;
Pilorget, Valerie (Sanofi) ;
Perfetti, Riccardo (Sanofi) ;
Khunti, Kamlesh (University of Leicester) ;
Universitat Autònoma de Barcelona
To describe in a real-world setting the achievement of physician-selected individualized HbA1c targets in individuals with type 2 diabetes, newly or recently initiated with basal insulin, and the association of hypoglycaemia with target achievement. [...]
2019 - 10.1111/dom.13673
Diabetes, Obesity and Metabolism, Vol. 21 Núm. 6 (june 2019) , p. 1429-1436
|
|
|
3.
|
|
12 p, 1.0 MB |
The importance of the initial period of basal insulin titration in people with diabetes
/
Khunti, Kamlesh (University of Leicester) ;
Giorgino, Francesco (University of Bari Aldo Moro) ;
Berard, Lori (Winnipeg Regional Health Authority) ;
Mauricio Puente, Dídac (Institut d'Investigació Biomèdica Sant Pau) ;
Harris, Stewart B. (Western University) ;
Universitat Autònoma de Barcelona
Achieving target glycaemic control is essential in people with diabetes to minimize the risk of long-term complications, and many people with type 2 diabetes will ultimately require basal insulin (BI) therapy to achieve their individualized glycaemic targets. [...]
2020 - 10.1111/dom.13946
Diabetes, Obesity and Metabolism, Vol. 22 Núm. 5 (january 2020) , p. 722-733
|
|
|
4.
|
|
10 p, 1.7 MB |
Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes : Barriers and solutions for improving uptake in routine clinical practice
/
Khunti, Kamlesh (NIHR Applied Research Collaboration - East Midlands) ;
Jabbour, Serge (Thomas Jefferson University) ;
Cos Claramunt, Francesc Xavier (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ;
Mudaliar, Sunder (Veterans Affairs Medical Center) ;
Mende, Christian (University of California San Diego) ;
Bonaca, Marc (University of Colorado School of Medicine) ;
Fioretto, Paola (University of Padua) ;
Universitat Autònoma de Barcelona
Recent advances in type 2 diabetes (T2D) research have highlighted the benefits of sodium-glucose co-transporter-2 (SGLT-2) inhibitors, including cardiovascular and renal protection. However, uptake rates of these drugs remain low in patients with T2D, particularly in subpopulations most likely to benefit from them. [...]
2022 - 10.1111/dom.14684
Diabetes, Obesity and Metabolism, Vol. 24 (march 2022) , p. 1187-1196
|
|
|
5.
|
|
15 p, 9.5 MB |
Low aerobic capacity in McArdle disease : A role for mitochondrial network impairment?
/
Villarreal-Salazar, M. (Hospital Universitari Vall d'Hebron) ;
Santalla, A. (Universidad Pablo de Olavide) ;
Real-Martinez, Alberto (Hospital Universitari Vall d'Hebron) ;
Nogales, Gisela (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Valenzuela, P.L. (Hospital Universitario 12 de Octubre (Madrid)) ;
Fiuza-Luces, C. (Hospital Universitario 12 de Octubre (Madrid)) ;
Andreu, A. L. (European Infrastructure for Translational Medicine) ;
Rodríguez-Aguilera, J.C. (Universidad Pablo de Olavide) ;
Martín, M.A. (Hospital Universitario 12 de Octubre (Madrid)) ;
Arenas, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ;
Vissing, J. (University of Copenhagen) ;
Lucia, A. (European University) ;
Krag, T.O. (University of Copenhagen) ;
Pinós Figueras, Tomàs (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
McArdle disease is caused by myophosphorylase deficiency and results in complete inability for muscle glycogen breakdown. A hallmark of this condition is muscle oxidation impairment (e. g. , low peak oxygen uptake (VO)), a phenomenon traditionally attributed to reduced glycolytic flux and Krebs cycle anaplerosis. [...]
2022 - 10.1016/j.molmet.2022.101648
Molecular metabolism, Vol. 66 (november 2022)
|
|
|
6.
|
|
26 p, 1.2 MB |
Bone Health in Adults With Prader-Willi Syndrome : Clinical Recommendations Based on a Multicenter Cohort Study
/
van Abswoude, Denise H. ;
Pellikaan, Karlijn ;
Rosenberg, Anna G. W. ;
Davidse, Kirsten ;
Coupaye, Muriel ;
Høybye, Charlotte ;
Markovic, Tania ;
Grugni, Graziano ;
Crinò, Antonino ;
Caixàs i Pedragós, Assumpta (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Poitou, Christine ;
Mosbah, Helena ;
Weir, Tessa ;
van Vlimmeren, Leo A. ;
Rutges, Joost P. H. J. ;
De Klerk, Luuk W. L. ;
Zillikens, M. Carola ;
van der Lely, Aart J. ;
de Graaff, Laura
Prader-Willi syndrome (PWS) is a rare complex genetic syndrome, characterized by delayed psychomotor development, hypotonia, and hyperphagia. Hormone deficiencies such as hypogonadism, hypothyroidism, and growth hormone deficiency are common. [...]
2022 - 10.1210/clinem/dgac556
The journal of clinical endocrinology & metabolism, Vol. 108 (september 2022) , p. 59-84
|
|
|
7.
|
|
27 p, 7.4 MB |
A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells
/
Garreta, Elena (Institute for Bioengineering of Catalonia. Grup de Pluripotència per a la regeneració d'òrgans. Institut de Ciència i Tecnologia de Barcelona) ;
Prado, Patricia (Institute for Bioengineering of Catalonia. Grup de Pluripotència per a la regeneració d'òrgans. Institut de Ciència i Tecnologia de Barcelona) ;
Stanifer, Megan (College of Medicine. University of Florida. Department of Molecular Genetics and Microbiology) ;
Monteil, Vanessa (Karolinska University Hospital and Karolinska Institutet (Suècia)) ;
Marco Giménez, Andrés (Institute for Bioengineering of Catalonia. Grup de Pluripotència per a la regeneració d'òrgans. Institut de Ciència i Tecnologia de Barcelona) ;
Ullate-Agote, Asier (Clínica Universidad de Navarra. Departamento de Hematología) ;
Moya Rull, Daniel (Institute for Bioengineering of Catalonia. Grup de Pluripotència per a la regeneració d'òrgans. Institut de Ciència i Tecnologia de Barcelona) ;
Vilas-Zornoza, Amaia (Clínica Universidad de Navarra. Departamento de Hematología) ;
Tarantino, Carolina (Institute for Bioengineering of Catalonia. Grup de Pluripotència per a la regeneració d'òrgans. Institut de Ciència i Tecnologia de Barcelona) ;
Romero, Juan Pablo (Instituto de Investigación Sanitaria de Navarra. Área de Hemato-Oncología. Centro de Investigación Médica Aplicada. Universidad de Navarra) ;
Jonsson, Gustav (Institute of Molecular Biotechnology of the Austrian Academy of Sciences) ;
Oria, Roger (Center for Bioengineering and Tissue Regeneration. UCSF) ;
Leopoldi, Alexandra (Institute of Molecular Biotechnology of the Austrian Academy of Sciences) ;
Hagelkruys, Astrid (Institute of Molecular Biotechnology of the Austrian Academy of Sciences) ;
Gallo, Maria (Institute for Bioengineering of Catalonia. Grup de Pluripotència per a la regeneració d'òrgans. Institut de Ciència i Tecnologia de Barcelona) ;
González Grassi, Federico (Institute for Bioengineering of Catalonia. Grup de Pluripotència per a la regeneració d'òrgans. Institut de Ciència i Tecnologia de Barcelona) ;
Domingo, Pere (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Gavaldà i Navarro, Aleix (Universitat de Barcelona. Departament de Bioquímica i Biomedicina Molecular) ;
Hurtado del Pozo, Carmen (Institute for Bioengineering of Catalonia. Grup de Pluripotència per a la regeneració d'òrgans. Institut de Ciència i Tecnologia de Barcelona) ;
Hasan Ali, Omar (Institute of Immunobiology. Cantonal Hospital St. Gallen) ;
Ventura-Aguiar, Pedro (Laboratori Experimental de Nefrologia I Trasplantament) ;
Campistol Plana, Josep M (Laboratori Experimental de Nefrologia I Trasplantament) ;
Prosper, Felipe (Clínica Universidad de Navarra. Departamento de Hematología) ;
Mirazimi, Ali (National Veterinary Institute) ;
Boulant, Steeve (Heidelberg University Hospital. Department of Infectious Diseases. Virology) ;
Penninger, Josef (Life Sciences Institute. University of British Columbia. Department of Medical Genetics) ;
Montserrat, Nuria (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina)
It is not well understood why diabetic individuals are more prone to develop severe COVID-19. To this, we here established a human kidney organoid model promoting early hallmarks of diabetic kidney disease development. [...]
2022 - 10.1016/j.cmet.2022.04.009
Cell Metabolism, Vol. 34 Núm. 6 (july 2022) , p. 857-873.e9
|
|
|
8.
|
|
8 p, 1.3 MB |
Impact of COVID19 pandemic on patients with rare diseases in Spain, with a special focus on inherited metabolic diseases
/
Rovira-Remisa, M. Mar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Moreira, Mónica (Universitat Autònoma de Barcelona) ;
Ventura-Wichner, Paula S (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Gonzalez-Alvarez, Pablo (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Mestres, Núria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Graterol Torres, Fredzzia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Joaquín, Clara (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Rodríguez-Palmero, Agustí (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez-Colls, Maria del Mar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Roche, Ana (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Ibáñez-Micó, Salvador (Hospital Universitario Virgen de la Arrixaca (Múrcia)) ;
López-Laso, Eduardo (Instituto Maimónides de Investigación Biomédica de Córdoba) ;
Méndez-Hernández, María Jesús (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Murillo-Vallés, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Monlleó-Neila, Laura (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Maqueda-Castellote, Elena (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Del Toro, Mireia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Felipe-Rucián, Ana (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Giralt López, Maria (Universitat Autònoma de Barcelona) ;
Cortès-Saladelafont, Elisenda (Universitat Autònoma de Barcelona)
The Covid-19 pandemic soon became an international health emergency raising concern about its impact not only on physical health but also on quality of life and mental health. Rare diseases are chronically debilitating conditions with challenging patient care needs. [...]
2023 - 10.1016/j.ymgmr.2023.100962
Molecular Genetics and Metabolism Reports, Vol. 35 (march 2023) , p. 100962
|
|
|
9.
|
|
53 p, 3.5 MB |
Low-density lipoprotein receptor-related protein 1 deficiency in cardiomyocytes reduces susceptibility to insulin resistance and obesity
/
Benitez Amaro, Aleyda (Institut d'Investigació Biomèdica Sant Pau) ;
Revuelta-López, Elena (Institut Germans Trias i Pujol) ;
Bornachea, Olga (Institut d'Investigació Biomèdica Sant Pau) ;
Cedó, Lídia (Institut d'Investigació Biomèdica Sant Pau) ;
Vea, Àngela (Institut d'Investigaciones Biomèdiques de Barcelona) ;
Herrero, Laura (Universitat de Barcelona. Departament de Bioquímica i Fisiologia) ;
Roglans, Nuria (Universitat de Barcelona. Departament de Farmacologia, Toxicologia i Química Terapèutica) ;
Soler-Botija, Carolina (Institut Germans Trias i Pujol) ;
Gonzalo Calvo, David de (Institut d'Investigaciones Biomèdiques de Barcelona) ;
Nasarre, Laura (Institut d'Investigaciones Biomèdiques de Barcelona) ;
Camino-López, Sandra (Institut d'Investigaciones Biomèdiques de Barcelona) ;
García, Eduardo (Institut d'Investigaciones Biomèdiques de Barcelona) ;
Mato, Eugenia (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Blanco Vaca, Francisco (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Bayés-Genís, Antoni (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sebastian, David (Universitat de Barcelona. Departament de Bioquímica i Biomedicina Molecular) ;
Laguna, Joan Carles (Universitat de Barcelona. Departament de Farmacologia, Toxicologia i Química Terapèutica) ;
Serra, Dolors (Universitat de Barcelona. Departament de Bioquímica i Fisiologia) ;
Zorzano Olarte, Antonio (Universitat de Barcelona. Departament de Bioquímica i Biomedicina Molecular) ;
Escolà-Gil, Joan Carles (Institut d'Investigació Biomèdica Sant Pau) ;
Llorente-Cortes, Vicenta (Institut Germans Trias i Pujol)
Background: Low-density lipoprotein receptor-related protein 1 (LRP1) plays a key role in fatty acid metabolism and glucose homeostasis. In the context of dyslipemia, LRP1 is upregulated in the heart. [...]
2020 - 10.1016/j.metabol.2020.154191
Metabolism: Clinical and Experimental, Vol. 160 (may 2020)
|
|
|
10.
|
|
6 p, 716.7 KB |
How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real-world setting?
/
Mauricio Puente, Dídac (Institut d'Investigació Biomèdica Sant Pau) ;
Westerbacka, J. (Sanofi) ;
Nicholls, C. (Sanofi) ;
Wu, Jasmanda (Sanofi) ;
Gupta, R. (Accenture) ;
Eliasson, B. (Department of Medicine. University of Gothenburg. Sahlgrenska University Hospital)
Randomized controlled trial (RCT) populations often do not reflect those typically seen in clinical practice. This retrospective, observational cohort study analysed the real-world data of people with type 2 diabetes (T2DM) prescribed basal insulin analogues from electronic medical records (EMRs) in the Explorys database, which includes data from 39 integrated healthcare systems in the United States, to determine how representative selected RCTs investigating insulin glargine 300 U/mL (Gla-300) are of T2DM populations in a real-world setting. [...]
2021 - 10.1111/dom.14264
Diabetes, Obesity and Metabolism, Vol. 23 Núm. 3 (march 2021) , p. 838-843
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
